Bioavailability determinants

Physical and Chemical Properties. The physical and chemical properties of lead and its compounds are sufficiently well defined to allow an estimation of the environmental fate of lead to be made (Howe 1981 HSDB 1996 Lide 1996 Merck 1989 Sax 1984 Sax and Lewis 1987). Availabilities of the various forms need to be modeled and the connectivities to bioaccessabilities and bioavailabilities determined. 

Relative bioavailability determinations are limited by what is known about the quantitative absorption of the reference substance. One cannot confidently predict absorption of the test substances based on relative bioavailability data. Relative bioavailability data, however, can be used to rank the test sources and to provide a basis for comparison among experiments. 

Bioavailability determined from blood AUC, corrected for dose. 

Bioavailability determined for cumulative amount excreted in urine (Au) after correcting for dose. 

Solid dispersions may create, in some cases, supersaturated solutions however overtime, drug could precipitate from such supersaturated solutions. If the drug precipitates as very Lne particles it could redissolve during Gl transit, leading to enhanced bioavailability. Determining the nature of... 

Bioavailability of a substance depends on its chemical or physical reactivity with various environmental components and its ability to be absorbed through the gastrointestinal tract, respiratory tract and/or skin of susceptible species. The bioavailability determines the fraction of emitted compounds that is able to interact with the biosystem of organisms per unit time. 

Chen, Z. and Mayer, L.M., Sedimentary metal bioavailability determined by the digestive constraints of marine deposit feeders Gut retention time and dissolved amino acids, Mar. Ecol.-Prog. Ser., 176, 139, 1999. 

Smolen VF. 1976. Theoretical and computational basis for drug bioavailability determinations using pharmacological data. I. General considerations and procedures . J. Pharmacokinet. Biopharm. 4 337. 

The human genome contains nearly 900 genes that encode transporters, of which over 300 are intracellular transporters [1] responsible for transporting a wide range of molecules across the membrane [2]. Further classification of these transporters into families such as the solute carrier dass (SLC) [3] and ATP binding cassette (ABC) family 4, 5] is possible. Transporters play a major role in clinical pharmacology as their adequate bioavailability determines the successful oral delivery of many therapeutics. Membrane transporter proteins are associated with drug absorption (uptake), tissue distribution (efflux and uptake), metabolism (hepatic efflux and uptake), and elimination (renal, biliary transporters, and breast milk efflux and uptake) [6, 7]. 

The ultrahigh sensitivity of AMS enables it to follow trace amounts of radioisotope-labeled drugs in animals and humans postadministration. In addition to microdose PK studies, AMS has been utilized in many aspects of pharmaceutical research, such as absolute bioavailability determination, mass balance and metabolite profiling, and identifications of DNA and protein adducts. 

Absolute bioavailability is a measure of the true extent of systemic absorption of an extravascularly administrated drug. Along with clearance and volume of distribution, absolute bioavailability is one of the important parameters to characterize PK. Low bioavailability of a drug can be caused by incomplete dissolution when administrated as a solid, inability to permeate membranes, and metabolic instability (first-pass metabolism). Despite the importance of absolute bioavailability, it is not routinely assessed due to the cost and toxicology requirements for such a study in a conventional study design, which requires an intravenous reference. Safety issues may arise due to solubility limitation and toxicity associated with Cmax effect. As a result, it is necessary to conduct a preclinical toxicological study with an IV formulation to ensure adequate human safety and potential problem. Bioavailability determined from animal models is not always predictive of that in human. 

In these studies, standard bioavailability variables such as the extent of bioavailability determined from area under the curve (AUC), rate of bioavailability related to peak plasma drug levels (Cmax) and time to peak (fmax) are determined. A more detailed presentation of the assumptions and interpretations of bioavailability data is given in Chapter 7. The bioavailability after administration in more distal parts of the intestine, such as the terminal ileum and different parts of the colon, is compared with a reference administration either as an oral solution or as a regional delivery to the upper small intestine. This is exemplified in Figure 4.18, which shows the plasma drug concentrations of metoprolol after administration to jejunum, terminal ileum and colon ascendens or transversum. 

D) Important because bioavailability determines what fraction of the administered dose reaches the systemic circulation... 

Gillespie, W. R. and Veng-Pedersen, R, Gastrointestinal bioavailability determination of in vivo release profiles of solid oral dosage forms by deconvolution, Biopharm. Drug Dispos., 6 351-355, 1985. 

Element losses together with element bioavailability determine how much of an element has to be provided through the diet to remain in element balance. For assessment of losses, a label needs to be administered once either orally or intravenously. Compartmental modeling techniques permit to calculate when the label has equilibrated with the natural element in all body compartments. When isotopic labeling has been achieved, continuous replacement of lost isotopic label with the natural element from the diet results in a continuous decline of the body s isotopic enrichment. The change in tracer to tracee ratio in blood corresponds directly to the fraction of the body s element inventory that has been lost and replaced. 

---